This is a proposal to conduct a series of studies on the clinical pharmacology of levo-alpha acetylmethadol (LAAM), which are directly relevant to its safety and clinical efficacy as an opiate maintenance/detoxification agent. Using within- and between-subject experimental designs, these studies will be conducted under rigorously controlled, double-blind conditions. Healthy adult volunteers, who are either opioid-dependent or opioid-experienced, will participate in these studies as inpatients on a residential research laboratory. The broad clinical issues to be addressed include characterization of the acute pharmacodynamic properties of LAAM, assessment of the opioid blockade properties of LAAM, and evaluation of various LAAM induction procedures. Specifically, the first study will assess the acute pharmacodynamic properties of LAAM when given orally and intravenously, and will provide information regarding safety, dose-effects, time course, and parenteral abuse liability. The second study will assess the development of cross- tolerance in response to LAAM maintenance, with a particular emphasis on the duration of blockade and the dose response relationships. The third study will characterize the time course and magnitude of withdrawal symptoms during transition from a short-acting opioid to LAAM, using the current FDA recommended dosing schedule for induction. The fourth study will characterize the crossover from methadone to LAAM in order to assess the therapeutic value of short-term methadone treatment prior to LAAM induction in unstabilized heroin addicts, and to assess the efficacy, safety and patient acceptability of the current induction schedule of LAAM in methadone-maintained patients. In summary, these studies will provide information on the pharmacodynamic properties of LAAM relevant to its clinical utility, efficacy and safety as a pharmacological adjunct for the treatment of intravenous opioid abusers. The development of new and effective pharmacotherapies for substance abuse, such as LAAM, will serve to reduce the medical complications stemming from intravenous drug abuse, including a reduction in the spread of HIV infection and AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA005273-09
Application #
5209644
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1996
Total Cost
Indirect Cost
Peirce, Jessica M; Kindbom, Kori A; Waesche, Matthew C et al. (2008) Posttraumatic stress disorder, gender, and problem profiles in substance dependent patients. Subst Use Misuse 43:596-611
Burke, Christopher K; Peirce, Jessica M; Kidorf, Michael S et al. (2008) Sleep problems reported by patients entering opioid agonist treatment. J Subst Abuse Treat 35:328-33
Wedam, Erich F; Bigelow, George E; Johnson, Rolley E et al. (2007) QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 167:2469-75
Sigmon, Stacey C (2007) Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement. Exp Clin Psychopharmacol 15:1-20
Carroll, C Patrick; Kidorf, Michael; Strain, Eric C et al. (2007) Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting. J Subst Abuse Treat 33:355-61
Sigmon, Stacey C; Moody, David E; Nuwayser, Elie S et al. (2006) An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 101:420-32
Lott, David C; Strain, Eric C; Brooner, Robert K et al. (2006) HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. J Subst Abuse Treat 31:187-94
Jones, Hendree E; Fitzgerald, Heather; Johnson, Rolley E (2005) Males and females differ in response to opioid agonist medications. Am J Addict 14:223-33
Lofwall, Michelle R; Brooner, Robert K; Bigelow, George E et al. (2005) Characteristics of older opioid maintenance patients. J Subst Abuse Treat 28:265-72
Disney, Elizabeth R; Kidorf, Michael; King, Van L et al. (2005) Prevalence and correlates of cocaine physical dependence subtypes using the DSM-IV in outpatients receiving opioid agonist medication. Drug Alcohol Depend 79:23-32

Showing the most recent 10 out of 44 publications